Last updated: September 8, 2026
Imipenem-cilastatin-relebactam, marketed in the United States as Recarbrio by Merck, is a hospital-reserved beta-lactam/beta-lactamase inhibitor combination. Its commercial opportunity is concentrated in multidrug-resistant Gram-negative infections, particularly carbapenem-resistant Enterobacterales with KPC or AmpC mechanisms. The product is strategically important in infectious-disease portfolios but is unlikely to become a mass-market pharmaceutical because antimicrobial stewardship limits routine use, treatment courses are short, and competing agents address overlapping pathogens.
Public filings do not report a separate, consistently disclosed Recarbrio revenue line. Its financial trajectory is therefore best assessed through regulatory expansion, hospital adoption, resistance epidemiology, competitive positioning, and portfolio strategy rather than standalone sales.
What is imipenem-cilastatin-relebactam and how does it work?
Recarbrio combines three active components:
| Component |
Function |
| Imipenem |
Carbapenem antibacterial that inhibits bacterial cell-wall synthesis |
| Cilastatin sodium |
Renal dehydropeptidase-I inhibitor that reduces imipenem degradation in the kidney |
| Relebactam |
Beta-lactamase inhibitor that protects imipenem from selected serine beta-lactamases |
The approved adult dose is imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg administered intravenously every six hours, with dosage adjustments for renal impairment. The product is used in serious infections where resistant Gram-negative pathogens limit standard therapies. [1]
Relebactam has meaningful activity against class A enzymes, including KPC carbapenemases, and class C AmpC beta-lactamases. It does not provide reliable coverage against metallo-beta-lactamases such as NDM, VIM, and IMP. Activity against OXA-type enzymes is also limited. This mechanism profile defines both the product’s clinical value and its market ceiling.
What FDA indications does Recarbrio have?
The FDA initially approved Recarbrio in July 2019 for adults with complicated urinary tract infections, including pyelonephritis, and complicated intra-abdominal infections in combination with metronidazole. [2]
The FDA expanded the label in 2020 to include hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in adults. The approval was supported by clinical data showing activity in serious hospital infections, although the product’s use remains concentrated in cases involving resistant or difficult-to-treat organisms. [3]
FDA regulatory timeline
| Date |
Regulatory event |
| July 2019 |
FDA approval for complicated urinary tract and intra-abdominal infections |
| 2019 |
Qualified Infectious Disease Product and priority-review framework supported development |
| October 2019 |
U.S. launch of Recarbrio |
| 2020 |
FDA approval expanded to hospital-acquired and ventilator-associated bacterial pneumonia |
| 2023-2024 |
Continued use under antimicrobial-stewardship and resistant-pathogen treatment protocols |
Recarbrio is not a biologic and does not face biosimilar competition. Its relevant follow-on risk is generic or alternative branded antibacterial competition.
How large is the market for imipenem-cilastatin-relebactam?
The addressable market is a high-value, low-volume segment of the hospital antibacterial market. Demand is driven by:
- Carbapenem-resistant Enterobacterales
- KPC-producing Klebsiella pneumoniae and Escherichia coli
- Serious hospital-acquired and ventilator-associated pneumonia
- Limited treatment options after resistance to cephalosporins, fluoroquinolones, or carbapenems
- Hospital infection-control requirements and antimicrobial-resistance surveillance
Demand is constrained by:
- Short treatment duration
- Restricted hospital formularies
- Stewardship programs that reserve the drug for documented or strongly suspected resistance
- Availability of alternative beta-lactam/beta-lactamase inhibitor products
- Lack of activity against metallo-beta-lactamase-producing pathogens
- Renal-dose complexity
- Budget pressure from hospitals and group purchasing organizations
The product is therefore a reserve antibiotic rather than a broad hospital formulary product. Its commercial performance depends more on resistance incidence and formulary access than on total inpatient admission volume.
How does Recarbrio compare with competing resistant-infection drugs?
Recarbrio competes primarily with ceftazidime-avibactam, meropenem-vaborbactam, cefiderocol, and ceftolozane-tazobactam.
| Product |
Active ingredients |
Principal competitive profile |
Key limitation |
| Recarbrio |
Imipenem/cilastatin/relebactam |
KPC and AmpC-producing Gram-negative infections; hospital pneumonia positioning |
Limited activity against metallo-beta-lactamases |
| Avycaz |
Ceftazidime/avibactam |
Broad use against KPC and some OXA-48-producing organisms |
Resistance can emerge during therapy; weaker positioning against some pathogens |
| Vabomere |
Meropenem/vaborbactam |
Strong KPC-focused activity |
Less useful against OXA-48 and metallo-beta-lactamases |
| Fetroja |
Cefiderocol |
Important option for some carbapenem-resistant and metallo-beta-lactamase-producing organisms |
Complex stewardship and clinical-positioning considerations |
| Zerbaxa |
Ceftolozane/tazobactam |
Pseudomonas aeruginosa and selected complicated infections |
Less effective against KPC carbapenemases |
| Zemdri |
Plazomicin |
Resistant Enterobacterales |
Nephrotoxicity and limited commercial uptake |
Recarbrio’s principal differentiation is the pairing of relebactam with imipenem. The combination can be useful when resistance involves KPC or AmpC enzymes but does not require a drug specifically directed at metallo-beta-lactamases. IDSA treatment guidance places newer beta-lactam agents at the center of therapy for resistant Enterobacterales, with selection based on enzyme type, infection site, susceptibility testing, and patient factors. [4]
What has been Recarbrio’s financial trajectory?
Recarbrio has a niche commercial profile rather than a blockbuster profile. Merck’s public reporting does not consistently provide a standalone annual revenue series for the product. The company generally reports many hospital and infectious-disease products within broader pharmaceutical categories, preventing a reliable product-level reconstruction from SEC filings alone. [5]
Commercial trajectory
| Period |
Financial and market interpretation |
| 2019 launch |
Entry into a growing resistant-pathogen market; initial uptake limited by reserve-use protocols |
| 2020-2021 |
Hospital disruption from COVID-19 reduced routine procedure volume but sustained demand for severe hospital infections |
| 2021-2023 |
Market matured as clinicians gained experience distinguishing KPC, AmpC, OXA, and metallo-beta-lactamase infections |
| 2023 onward |
Revenue potential remained tied to resistance surveillance, diagnostic turnaround, and hospital contracting rather than broad prescription growth |
The product’s short-course hospital model produces lower recurring revenue per patient than chronic therapies. Revenue can rise when hospitals experience outbreaks or higher rates of carbapenem resistance, but those same events do not create predictable, scalable demand.
A reasonable commercial classification is:
- High clinical value in a narrow population.
- Moderate pricing power because alternatives are limited in selected cases.
- Low volume because stewardship restricts empirical use.
- High substitution risk within the new-generation antibacterial class.
- Limited probability of blockbuster status without major resistance-driven expansion or a new indication.
Hospital antimicrobial products also face delayed or restricted formulary adoption. Pharmacy and therapeutics committees often require susceptibility data, infectious-disease approval, or prior authorization before dispensing. Those controls reduce inappropriate use but slow revenue conversion after regulatory approval.
What patent and exclusivity rights protect imipenem-cilastatin-relebactam?
The principal intellectual-property value is associated with relebactam and the fixed combination, not with imipenem or cilastatin individually. Imipenem-cilastatin is an established generic combination with extensive prior-art exposure. A generic manufacturer would need to address the relebactam component, the combination claims, formulation claims, and any relevant method-of-use claims.
Regulatory exclusivity
The 2019 approval provided five years of new chemical entity exclusivity for relebactam, subject to statutory interpretation of the active moiety and FDA exclusivity records. That period would have ended in 2024 unless another regulatory exclusivity mechanism applied.
Recarbrio also received Qualified Infectious Disease Product treatment under the Generating Antibiotic Incentives Now framework. QIDP status can provide a five-year extension to an applicable patent or non-patent exclusivity period. It does not create a separate, universally applicable market-exclusivity date independent of the underlying patent or regulatory right. [6]
Patent protection
The relevant U.S. patent estate is expected to include claims directed to:
- Relebactam composition of matter
- Pharmaceutical combinations containing relebactam and imipenem
- Treatment of beta-lactamase-producing bacterial infections
- Intravenous formulations
- Dosing and renal-adjustment regimes
- Manufacturing and solid-state forms, where claimed
A single patent-expiration date should not be used to estimate generic entry. The commercial blocking position depends on the Orange Book-listed patents, terminal disclaimers, patent-term adjustment, pediatric extensions, and the scope of any Paragraph IV certification.
What is the Orange Book status of Recarbrio?
Recarbrio is an FDA-approved small-molecule drug subject to Orange Book listing. The Orange Book is the controlling source for approved product information, therapeutic-equivalence evaluations, and listed patent certifications. [7]
The practical generic-entry issue is not whether imipenem and cilastatin are individually generic. It is whether an applicant can obtain approval for the same three-component combination and address the listed relebactam-related patents.
A generic applicant could pursue:
- Paragraph III certification, accepting patent expiry before launch
- Paragraph IV certification, asserting that listed patents are invalid, unenforceable, or not infringed
- A design-around product with a different formulation or dosing strategy, if legally and clinically feasible
- An abbreviated pathway that does not create a direct substitutable equivalent
Because the product is an intravenous fixed combination, development requires more than reproducing an oral tablet. Manufacturing consistency, sterility, compatibility, stability, container closure, and clinical pharmacology are important barriers.
Which companies are challenging Recarbrio patents?
No major, publicly established U.S. Paragraph IV litigation campaign against Recarbrio had become a defining commercial event in the public record through the latest broadly available reporting period. The absence of a high-profile challenge does not establish that no ANDA applicant has made a certification. It indicates that the product had not generated litigation comparable to major chronic-care products.
Potential challengers would include large generic manufacturers with sterile injectable capabilities. The most credible candidates would be companies with established hospital-injectable portfolios, including Sandoz, Fresenius Kabi, Hikma, Baxter, Pfizer’s injectables business, and Viatris. A generic launch would require regulatory approval, commercial manufacturing capacity, and hospital-contract access.
What generic entry risks exist for Recarbrio?
Generic entry risk is moderate over the long term but lower in the near term than for a simple, older injectable antibiotic.
The main barriers are:
- Relebactam patent claims
- Fixed-dose combination requirements
- Sterile injectable manufacturing
- Limited volume relative to manufacturing complexity
- Need for hospital contracting
- Product-specific stability and compatibility studies
- Competition from already established resistant-infection therapies
The launch scenario most likely to affect pricing is not immediate substitution across the entire class. It is a staggered entry in which one or more injectable manufacturers offer a lower-priced imipenem-cilastatin-relebactam product to hospitals and government purchasers. Because antimicrobial stewardship restricts use, price erosion may be significant without producing a large increase in total unit volume.
What manufacturing and clinical barriers protect the franchise?
The product has several practical barriers beyond patent rights.
Manufacturing barriers
Recarbrio requires a sterile intravenous presentation with controlled component ratios and reliable stability. Generic developers must manage:
- Sterile fill-finish capacity
- Compatibility between imipenem, cilastatin, and relebactam
- Degradation control
- Powder or solution stability
- Packaging and reconstitution requirements
- Batch release testing
Clinical and commercial barriers
Hospitals must maintain protocols for:
- Susceptibility testing
- Renal-dose adjustment
- Carbapenem-resistance confirmation
- Restricted prescribing
- Infectious-disease consultation
- Monitoring for emergence of resistance
These controls protect the incumbent from some casual substitution but also limit product demand. A hospital may prefer a competing agent with a better local antibiogram fit, simpler dosing, or stronger supply reliability.
What licensing deals affect imipenem-cilastatin-relebactam?
Merck is the principal commercial sponsor and patent-holder entity associated with relebactam and Recarbrio. Relebactam was developed within Merck’s antibacterial research portfolio, including assets associated with the company’s acquisition of Cubist Pharmaceuticals. Public materials identify Merck as the central commercial and regulatory party for Recarbrio rather than a product dependent on a large external licensing network.
The relevant strategic transaction was Merck’s acquisition of Cubist in 2015. Cubist had a major antibacterial portfolio and infectious-disease development infrastructure. That transaction strengthened Merck’s position in hospital anti-infectives and provided a platform for commercializing products such as Zerbaxa and Recarbrio. [8]
How strong is the patent estate and commercial position?
The patent estate is stronger than the estate for imipenem-cilastatin alone because relebactam is a newer component and the three-drug combination has separate technical and clinical claim opportunities. Its strength is moderated by the narrow market and by the possibility that a competitor can address the same resistance mechanism with a different beta-lactam/beta-lactamase inhibitor combination.
| Risk factor |
Assessment |
| Composition-of-matter protection |
Historically important and potentially strong for relebactam |
| Combination protection |
Meaningful, but vulnerable to claim-construction and obviousness challenges |
| Method-of-use protection |
Potentially useful for resistant Gram-negative infections |
| Formulation protection |
Relevant to injectable generic development |
| Patent litigation exposure |
Lower visibility than major chronic drugs, but Paragraph IV risk remains |
| Biosimilar risk |
Not applicable |
| Generic substitution risk |
Moderate over the longer term |
| Competitive substitution risk |
High within the resistant Gram-negative antibiotic class |
| Revenue durability |
Dependent on resistance epidemiology and stewardship access |
What is the outlook for generic launch and revenue exposure?
A generic launch would probably occur first in the United States, where Orange Book certifications and hospital purchasing create a defined route to market. European and other geographic launches would depend on national patent status, regulatory approval, tender systems, and local reimbursement.
The commercial impact would depend on three variables:
- Whether the first entrant receives approval before all relevant U.S. patent protections expire.
- Whether the entrant secures hospital contracts.
- Whether physicians continue to prefer Recarbrio over Avycaz, Vabomere, Fetroja, and other alternatives.
Merck’s revenue exposure is likely meaningful within its infectious-disease portfolio but small relative to its oncology, vaccines, and immunology businesses. Recarbrio can protect strategic access to the hospital-antibiotic market without materially changing Merck’s consolidated financial trajectory.
Key Takeaways
- Imipenem-cilastatin-relebactam is marketed in the U.S. as Recarbrio.
- The product targets serious resistant Gram-negative infections, especially KPC and AmpC-producing organisms.
- Its market is clinically important but volume-limited by antimicrobial stewardship.
- Merck does not consistently report standalone Recarbrio revenue, so product-level financial modeling requires indirect market indicators.
- Imipenem and cilastatin are mature generic components; relebactam and the fixed combination carry most of the differentiated IP value.
- FDA new chemical entity exclusivity associated with the 2019 approval reached its five-year endpoint in 2024, while QIDP-related patent extension rights may affect patent timing.
- No biosimilar risk exists because Recarbrio is a small-molecule antibacterial.
- Generic risk is moderate over the long term, but sterile injectable manufacturing and limited market size raise entry barriers.
- Avycaz, Vabomere, Fetroja, and Zerbaxa are the primary competitive products.
- Revenue is likely to remain niche and resistance-driven rather than evolve into a blockbuster trajectory.
FAQs about imipenem-cilastatin-relebactam
Is Recarbrio the same as imipenem-cilastatin?
No. Imipenem-cilastatin is a two-component carbapenem product. Recarbrio adds relebactam, a beta-lactamase inhibitor intended to restore imipenem activity against selected resistant bacteria.
Does relebactam treat metallo-beta-lactamase-producing organisms?
No. Relebactam does not reliably inhibit metallo-beta-lactamases such as NDM, VIM, and IMP. Susceptibility testing and resistance-mechanism identification are necessary before selecting therapy.
Is there a generic version of Recarbrio?
A generic version would need to match the three-component intravenous product and address applicable Orange Book patents. Imipenem-cilastatin generics do not substitute for imipenem-cilastatin-relebactam.
Which is stronger against KPC-producing Enterobacterales, Recarbrio or Vabomere?
Both have important KPC-focused activity. Selection depends on susceptibility results, infection site, renal function, dosing requirements, local resistance patterns, and hospital protocols.
Can Recarbrio become a major commercial antibiotic?
Its clinical importance can grow as carbapenem resistance increases, but its revenue ceiling is limited by short treatment courses, restricted prescribing, competing beta-lactamase inhibitor combinations, and stewardship controls.
References
- Merck & Co., Inc. (2023). Recarbrio prescribing information. U.S. Food and Drug Administration.
- U.S. Food and Drug Administration. (2019, July 17). FDA approves new treatment for complicated urinary tract and intra-abdominal infections.
- U.S. Food and Drug Administration. (2020, June 29). FDA approves antibacterial Recarbrio for hospital-acquired and ventilator-associated bacterial pneumonia.
- Infectious Diseases Society of America. (2024). IDSA 2024 guidance on the treatment of antimicrobial-resistant Gram-negative infections.
- Merck & Co., Inc. (2024). 2023 annual report.
- U.S. Congress. (2012). Food and Drug Administration Safety and Innovation Act, Generating Antibiotic Incentives Now provisions.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- Merck & Co., Inc. (2015). Merck completes acquisition of Cubist Pharmaceuticals.
